TENOFOVIR DISOPROXIL fumarate 300mg, eq. 245mg base, tab.

STD DORATENO3T-

Valid Article

Former Code(s): -X DORAZBD0426
6.4.2.1 - Nucleoside/Nucleotide reverse transcriptase inhibitors
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
6.4.4.1.1 - Nucleoside/Nucleotide reverse transcriptase inhibitors
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
J05AF07
Anatomical Therapeutic Chemical Classification according to WHOCC
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)

This combination does not exist.

See Related

Add article to list

   

Add Kit To Wishlist

   

TENOFOVIR (TDF)

Therapeutic Action

Antiretroviral, nucleotide reverse transcriptase inhibitor (NRTI)

Indications

Chronic hepatitis B virus (HBV) infection in adults and children from 12 years of age.

For HIV treatment, use fixed-dose combination containing tenofovir, in combination with other ARVs.

Instructions for use

300 mg tenofovir fumarate is equivalent to 245 mg tenofovir base.

Entecavir (ETV), another antiretroviral NRTI, is recommended as first-line treatment for chronic hepatitis B virus infection in children aged 2 to 12 years.

Fixed-dose combinations of TDF/3TC (lamivudine) or TDF/FTC (emtricitabine) are recommended as alternative regimens where TDF monotherapy is not available.

Precautions for Use

Closely monitor renal function .

Storage

Below 25ºC